Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: Phase i study results

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 703-712

  Heath, Elisabeth I ^a   Blumenschein Jr , George R ^b   Cohen, Roger B ^c   Lorusso, Patricia M ^a   Loconte, Noelle K ^d   Kim, Sindy T ^e   Ruiz Garcia, Ana ^e   Chao, Richard C ^e   Wilding, George ^d  

^a KARMANOS CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e PFIZER INC   (United States)

Author keywords

Antiangiogenesis; Chemotherapy; NSCLC; Phase I; Solid tumor; Sunitinib

Indexed keywords

CARBOPLATIN; DRUG METABOLITE; PACLITAXEL; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMOPTYSIS; HUMAN; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PAPILLEDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PYRROLES; TREATMENT OUTCOME;

EID: 80054683755     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1536-1     Document Type: Article

References (35)

1. VL Keedy AB Sandler 2007 Inhibition of angiogenesis in the treatment of non-small cell lung cancer Cancer Sci 98 1825 1830 17892508 10.1111/j.1349-7006. 2007.00620.x 1:CAS:528:DC%2BD2sXhsVahtbfM
2. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: NSCLC v.2.2009. Available via http://www.nccn.org/ professionals/physician-gls/PDF/nscl.pdf
3. SP Khosravi PI Fernandez 2008 Tumoral angiogenesis: review of the literature Cancer Invest 26 104 108 10.1080/07357900701662509
4. M Tallquist A Kazlauskas 2004 PDGF signaling in cells and mice Cytokine Growth Factor Rev 15 205 213 15207812 10.1016/j.cytogfr.2004.03.003 1:CAS:528:DC%2BD2cXltVKht7k%3D
5. LB Saltz S Clarke E az-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 20 2013 2019 10.1200/JCO.2007.14.9930
6. NJ Robert V Dieras J Glaspy, et al. 2009 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 27 15s 1005 Abstract
7. PL Nghiemphu W Liu Y Lee, et al. 2009 Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience Neurology 72 1217 1222 19349600 10.1212/01.wnl.0000345668.03039.90 1:CAS:528:DC%2BD1MXjslKrsrs%3D
8. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI
9. J Homsi AI Daud 2007 Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors Cancer Control 14 285 294 17615535
10. G Bergers S Song N Meyer-Morse E Bergsland D Hanahan 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 1287 1295 12727920 1:CAS:528: DC%2BD3sXjsFCrsr4%3D
11. TJ Abrams LB Lee LJ Murray NK Pryer JM Cherrington 2003 SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 471 478 12748309 1:CAS:528:DC%2BD3sXkvVersbw%3D
12. DB Mendel AD Laird X Xin, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D
13. RJ Motzer TE Hutson P Tomczak, et al. 2006 Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Proc Am Soc Clin Oncol 24 2s
14. Motzer RJ, Figlin R, Hutson TE et al (2007) Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol ASCO Annual meeting proceedings part I. vol 25, no. 18S (20 June Suppl):(Abstract 5024)
15. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL
16. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
17. M Edgerly T Fojo 2008 Is there room for improvement in adverse event reporting in the era of targeted therapies? 1 J Natl Cancer Inst 100 240 242 18270340 10.1093/jnci/djm324 1:CAS:528:DC%2BD1cXisVKgs7s%3D
18. Rigas JR (2004) Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 Suppl 2: 16-23
19. AB Custodio Carretero JA Garcia Saenz JL Gonzalez Larriba, et al. 2008 Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review Clin Transl Oncol 10 560 571 18796373 10.1007/s12094-008-0251-x
20. EA Perez 2004 Carboplatin in combination therapy for metastatic breast cancer Oncologist 9 518 527 15477636 10.1634/theoncologist.9-5-518 1:CAS:528:DC%2BD2cXps1amtr4%3D
21. HJ Burstein AD Elias HS Rugo, et al. 2008 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 1810 1816 18347007 10.1200/JCO.2007.14.5375 1:CAS:528: DC%2BD1cXmsFemsb8%3D
22. MA Socinski S Novello JR Brahmer, et al. 2008 Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 650 656 18235126 10.1200/JCO.2007.13.9303 1:CAS:528: DC%2BD1cXis1alsbs%3D
23. M Kulke HJ Lenz N Meropol, et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 3403 3410 18612155 10.1200/JCO.2007.15.9020 1:CAS:528:DC%2BD1cXpvVWitro%3D
24. Kozloff M, Chuang E, Starr A et al (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 21:1436-1441
25. F Robert A Sandler JH Schiller, et al. 2010 Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study Cancer Chemother Pharmacol 66 669 680 20043166 10.1007/s00280-009-1209-0 1:CAS:528:DC%2BC3cXoslymtbw%3D
26. Chiorean EG, Sweeney CJ, Verschraegen CF et al (2008) Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): a phase I dose-finding study. J Clin Oncol 26: 2008 (20 May suppl; abstract 3562)
27. G Fountzilas HP Kalofonos U Dafni, et al. 2004 Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic cooperative oncology group 1 Ann Oncol 15 1517 1526 15367413 10.1093/annonc/mdh395 1:STN:280:DC%2BD2cvlvVKjsQ%3D%3D
28. Karp DD, Novello S, Cardenal F et al (2009) Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 27 (15s) 8072: 15s (suppl; abstract)
29. S Leong RB Cohen DL Gustafson, et al. 2009 Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study 1 J Clin Oncol 27 4413 4421 19652058 10.1200/JCO.2008.21.7422 1:CAS:528:DC%2BD1MXht1WisbnK
30. Pfizer Inc. (2008) Data on file
31. D Beulz-Riche J Robert C Riche D Ratanasavanh 2002 Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes Cancer Chemother Pharmacol 49 274 280 11914905 10.1007/s00280-001-0415-1 1:CAS:528: DC%2BD38XitFeitbg%3D
32. TL Nielsen BB Rasmussen JP Flinois P Beaune K Brosen 1999 In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes J Pharmacol Exp Ther 289 31 37 10086984 1:CAS:528:DyaK1MXit1Kiu7w%3D
33. RL Walsky EA Gaman RS Obach 2005 Examination of 209 drugs for inhibition of cytochrome P450 2C8 J Clin Pharmacol 45 68 78 15601807 10.1177/ 0091270004270642 1:CAS:528:DC%2BD2MXks1Sls7k%3D
34. B Rochat JM Morsman GI Murray WD Figg HL McLeod 2001 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296 537 541 11160641 1:CAS:528:DC%2BD3MXoslejtQ%3D%3D
35. M Baumhakel D Kasel RA Rao-Schymanski, et al. 2001 Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes Int J Clin Pharmacol Ther 39 517 528 11770832 1:CAS:528:DC%2BD38XivVymtQ%3D%3D